Allergan plc (NYSE:AGN) Receives $177.67 Consensus PT from Analysts
Allergan plc (NYSE:AGN) has been assigned an average recommendation of “Hold” from the twenty-five analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $180.32.
A number of analysts have recently issued reports on AGN shares. Royal Bank of Canada reaffirmed a “hold” rating and issued a $178.00 price objective on shares of Allergan in a research report on Thursday, August 8th. Mizuho cut Allergan from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $171.00 to $188.00 in a report on Wednesday, June 26th. Guggenheim cut Allergan from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. TheStreet raised Allergan from a “d+” rating to a “c” rating in a report on Friday, July 12th. Finally, Goldman Sachs Group began coverage on Allergan in a report on Tuesday, May 28th. They set a “neutral” rating and a $154.00 price target for the company.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Liberty Wealth Management LLC raised its holdings in Allergan by 35.3% in the 2nd quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after acquiring an additional 67 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in Allergan by 1.8% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 4,274 shares of the company’s stock valued at $626,000 after acquiring an additional 75 shares in the last quarter. Berman Capital Advisors LLC raised its holdings in Allergan by 48.8% in the 1st quarter. Berman Capital Advisors LLC now owns 238 shares of the company’s stock valued at $34,000 after acquiring an additional 78 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Allergan by 43.1% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock valued at $44,000 after acquiring an additional 78 shares in the last quarter. Finally, Founders Financial Securities LLC raised its holdings in Allergan by 2.0% in the 1st quarter. Founders Financial Securities LLC now owns 4,300 shares of the company’s stock valued at $630,000 after acquiring an additional 84 shares in the last quarter. 77.81% of the stock is owned by hedge funds and other institutional investors.
Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company had revenue of $4.09 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same period last year, the firm posted $4.42 earnings per share. The business’s revenue was down .8% on a year-over-year basis. As a group, research analysts predict that Allergan will post 16.64 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th will be issued a $0.74 dividend. The ex-dividend date is Monday, August 12th. This represents a $2.96 annualized dividend and a yield of 1.88%. Allergan’s dividend payout ratio is presently 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.